Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management Strategies-Reference-Cited by-同舟云学术

Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management Strategies

Published:2023-02 Issue:1 Volume:5 Page:1-21
ISSN:2666-0873
Container-title:JACC: CardioOncology
language:en
Short-container-title:JACC: CardioOncology

Author:

Georgiopoulos Georgios,Makris Nikolaos^ORCID,Laina Ageliki,Theodorakakou Foteini,Briasoulis Alexandros,Trougakos Ioannis P.,Dimopoulos Meletios-Athanasios,Kastritis Efstathios,Stamatelopoulos Kimon

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Oncology

Reference139 articles.

1. Cancer statistics, 2021;Siegel;CA Cancer J Clin,2021

2. Cellular quality control by the ubiquitin-proteasome system and autophagy;Pohl;Science,2019

3. The ubiquitin-proteasome system: focus on the heart;Zolk;Cardiovasc Res,2006

4. The 26 S proteasome: from basic mechanisms to drug targeting;Navon;J Biol Chem,2009

5. Autophagy activation can partially rescue proteasome dysfunction-mediated cardiac toxicity;Papanagnou;Aging Cell,2022

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms, Clinical Management and Innovative Treatment;Drug Design, Development and Therapy;2024-09

2. Cancer and Heart Failure: Dangerous Liaisons;Journal of Cardiovascular Development and Disease;2024-08-27

3. Intercellular pathways of cancer treatment-related cardiotoxicity and their therapeutic implications: the paradigm of radiotherapy;Pharmacology & Therapeutics;2024-08

4. Severe Heart Failure after Using Bortezomib in a Patient with Multiple Myeloma and Cardiac Amyloidosis of Normal Wall Thickness;ACTA CARDIOL SIN;2024

5. Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide;Blood Reviews;2024-07